Xu Jing, Qian Shu-Shu, Chen Yao-Guo, Li Dong-Yun, Yan Qian
Dongzhimen Hospital,Beijing University of Chinese Medicine Beijing 100700,China.
the First Medical College of Guangzhou University of Chinese Medicine Guangzhou 510405,China.
Zhongguo Zhong Yao Za Zhi. 2019 Jun;44(12):2627-2636. doi: 10.19540/j.cnki.cjcmm.20190304.003.
To evaluate the effectiveness and safety of Huachansu in the treatment of cancer-related pain,four Chinese databases( CNKI,VIP,Wan Fang,Sino Med) and three English databases( Cochrane Library,Medline,PubMed) were systematically and comprehensively retrieved since the establishment of each database to October 2018. Randomized controlled trials( RCTs) for the treatment of cancer-related pain with Huachansu were screened out according to pre-established inclusion criteria and exclusion criteria. Rev Man5. 3 software was used for Meta-analysis. A total of 241 articles were retrieved,and finally 10 studies were included. The total sample size was 1 293,including 648 in the experimental group and 645 in the control group. The overall quality of the included studies was generally low. The results of Meta-analysis showed that Huachansu combined with Western medicine acesodynes was superior to the single use of Western medicine acesodynes in the treatment of short-term pain relief,improvement of quality of life and reduction of constipation,nausea and vomiting,dizziness,drowsiness,anorexia and other adverse reactions. And it also has the advantage of a shorter onset time and longer duration time of analgesia,but cannot reduce the incidence of dysuria. Based on the findings,Huachansu had a certain effect in the treatment of cancer-related pain,and a significant positive effect on the improvement of quality of life and the reduction of adverse reactions. No serious adverse reactions occurred. However,due to the small number of studies included,the low quality of the included studies,published biases and other restrictions,the evidence in this study has a low quality,and the conclusion shall be adopted with caution. The effectiveness and safety of Huachansu in the treatment of cancer-related pain remained to be further confirmed in the future with a well-designed,rigorous,and standardized report,with a large sample size,multiple centers,and sufficient follow-up time for randomized controlled trials.
为评价华蟾素治疗癌痛的有效性和安全性，自各数据库建库至2018年10月，系统全面地检索了4个中文数据库（中国知网、维普、万方、中国生物医学文献数据库）和3个英文数据库（考克兰图书馆、医学期刊数据库、医学文献数据库）。根据预先设定的纳入标准和排除标准，筛选出华蟾素治疗癌痛的随机对照试验。采用Rev Man5. 3软件进行Meta分析。共检索到241篇文献，最终纳入10项研究。总样本量为1 293例，其中试验组648例，对照组645例。纳入研究的整体质量普遍较低。Meta分析结果显示，华蟾素联合西药镇痛药在短期缓解疼痛、改善生活质量及减少便秘、恶心呕吐、头晕、嗜睡、厌食等不良反应方面优于单纯使用西药镇痛药。且具有起效时间短、镇痛持续时间长的优势，但不能降低排尿困难的发生率。基于研究结果，华蟾素在癌痛治疗中具有一定作用，对改善生活质量和减少不良反应有显著积极作用。未发生严重不良反应。然而，由于纳入研究数量较少、纳入研究质量较低、发表偏倚等限制，本研究证据质量较低，结论应谨慎采用。华蟾素治疗癌痛的有效性和安全性仍有待未来通过设计良好、严谨、规范，样本量大、多中心、随访时间充足的随机对照试验进一步证实。
